NIH-Funding

Innovative Questions in Symptom Science and Genomics (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 03:49
Funding Opportunity PA-18-471 from the NIH Guide for Grants and Contracts. This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.
Categories: NIH-Funding

Personalized Strategies to Manage Symptoms of Chronic Illness (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 03:49
Funding Opportunity PA-18-472 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.
Categories: NIH-Funding

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

NIH Funding Announcements - Mon, 12/18/2017 - 02:44
Funding Opportunity PAR-18-513 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase I to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.
Categories: NIH-Funding

Self-Management for Health in Chronic Conditions (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 02:09
Funding Opportunity PA-18-376 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Categories: NIH-Funding

Self-Management for Health in Chronic Conditions (R21 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 02:06
Funding Opportunity PA-18-384 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Categories: NIH-Funding

Self-Management for Health in Chronic Conditions (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 02:06
Funding Opportunity PA-18-474 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of self-management for health in chronic conditions. This FOA focuses on self-management as a mainstream science to reduce the burden of chronic illnesses/conditions.
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Fri, 12/15/2017 - 18:07

Looking at how few awards they issue (29 current awards listed in RePORTER for all of CDC & FDA combined), I am sure there is no payline but that awards made based on score & programmatic preferences. I would suggest you contact the appropriate individual(s) at the CDC (depending on which center/program best fits your work) and the FDA for information both on whether your science would be a priority (but look closely at past awards for clues, too) and how they select applications for funding. You can find the contacts both in the PDF that SaG helpfully cited (thank you!) and at https://sbir.nih.gov/engage/ic-contacts

Categories: NIH-Funding

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R21 Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 13:40
Funding Opportunity PA-18-499 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.
Categories: NIH-Funding

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 13:40
Funding Opportunity PA-18-498 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks to stimulate research focused on identification of the key barriers to effective end-of-life and palliative care (EOLPC) health literacy in diverse settings and populations, and to create novel strategies, interventions, and models of care to improve EOLPC health literacy, with the goal of improving outcomes for individuals with serious, advanced illness and their families and caregivers.
Categories: NIH-Funding

Human Subjects Mechanistic and Minimal Risk Studies (R21 Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 13:08
Funding Opportunity PA-18-500 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to encourage applications that seek to conduct studies of the visual system. Eligible applications may be either: Those that involve human subjects, but are not NIH-defined clinical trials (see NOT-OD-15-015); or Those that are NIH-defined clinical trials and are designed to address either: 1) mechanisms underlying human vision in health and disease; or 2) interventions that entail procedures with minimal risk to subjects. More information about eligibility can be found in Part 2 Section III.3. A mechanistic trial is defined as "A study designed to understand a biological or behavioral process, the pathophysiology of a disease, or the mechanism of action of an intervention. "Minimal risk" means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. NIH-defined clinical trial applications that are neither mechanistic nor minimal risk are not eligible for this FOA. Large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials are not appropriate for this FOA. Applicants are strongly advised to consult with NEI program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.
Categories: NIH-Funding

NIBIB Exploratory/Developmental Research Grant Program (R21) (Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 13:06
Funding Opportunity PAR-18-433 from the NIH Guide for Grants and Contracts. This FOA will support exploratory/developmental research projects of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.
Categories: NIH-Funding

By: SaG

WriteEdit-Grant Questions Blog - Fri, 12/15/2017 - 12:52

You can find all of the HHS topics (including CDC, FDA, NIH etc.) in this pdf. https://sbir.nih.gov/sites/default/files/2017-2_SBIR-STTR-topics.pdf

I am not sure FDA or CDC publish a payline for SBIRs. But, if anyone can find it W.E. can.

Categories: NIH-Funding

Sleep disorders and circadian clock disruption in Alzheimers disease and other dementias of aging (R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Fri, 12/15/2017 - 12:42
Funding Opportunity PAR-18-497 from the NIH Guide for Grants and Contracts. This FOA is aimed at molecular, cellular, genetic, epigenetic, and systems biology approaches to advance basic and clinical research on the causes and consequences of sleep deficiency and circadian clock dysfunction in Alzheimer's disease, and the roles of sleep and the circadian clock as modifiers of the progression of neurodegeneration.
Categories: NIH-Funding

Pragmatic Trials of Managing Multimorbidity in Alzheimers Disease (R01 Clinical Trial Required)

NIH Funding Announcements - Fri, 12/15/2017 - 12:31
Funding Opportunity RFA-AG-18-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and related dementia (ADRD).
Categories: NIH-Funding

Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 12:20
Funding Opportunity RFA-DA-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline.
Categories: NIH-Funding

Synthetic Biology for Engineering Applications (R01) (Clinical Trial Optional)

NIH Funding Announcements - Fri, 12/15/2017 - 12:08
Funding Opportunity PAR-18-434 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early Stage Investigators in Synthetic Biology are especially encouraged to apply.
Categories: NIH-Funding

Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimers Disease Risk (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Fri, 12/15/2017 - 12:00
Funding Opportunity RFA-AG-18-029 from the NIH Guide for Grants and Contracts. This funding opportunity announcement invites comprehensive, cross-disciplinary studies aimed at building predictive molecular models of cognitive resilience based on high-dimensional molecular data collected in individuals who remain free of dementia despite being at high risk for Alzheimers disease.
Categories: NIH-Funding

Exosomes: From Biogenesis and Secretion to the Early Pathogenesis of Alzheimer's Disease (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Fri, 12/15/2017 - 11:02
Funding Opportunity RFA-AG-18-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the role of exosome biogenesis and secretion in modulating and propagation of early pathogenesis in sporadic and late-onset Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of molecular machines that are responsible for exosome biogenesis and the secretion of exosomal cargo molecules in AD.
Categories: NIH-Funding

From Association to Function in the Alzheimers Disease Post-Genomics Era (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Fri, 12/15/2017 - 10:44
Funding Opportunity RFA-AG-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits innovative and collaborative research focused on understanding the structure and function of proteins or protein complexes regulated by different AD genetic variants that have been identified to be associated with the sporadic and late onset Alzheimers disease (AD). Specifically, NIA is interested in identifying and developing more effective and integrated platforms to screen protein functions, protein-protein interaction, protein complexes and their regulation by AD genetic variants prior to any in-depth mechanistic studies. The program encourages collaborative research projects that will translate initial GWAS discovery into functional and phenotypical insights and ultimately lead to understand the complex biology of AD.
Categories: NIH-Funding